Therapy response in AML: a tale of two T cells.
作者信息
Penter Livius, Wu Catherine J
机构信息
Charité-Universitätsmedizin Berlin.
Berlin Institute of Health at Charité-Universitätsmedizin Berlin.
出版信息
Blood. 2024 Sep 12;144(11):1134-1136. doi: 10.1182/blood.2024024593.
Abstract
摘要
相似文献
1
Therapy response in AML: a tale of two T cells.
Blood. 2024 Sep 12;144(11):1134-1136. doi: 10.1182/blood.2024024593.
2
Anti-CD19 CAR-T cell therapy in relapsed/refractory t(8;21) acute myeloid leukemia with aberrant CD19 expression.
Front Immunol. 2025 Jul 21;16:1617589. doi: 10.3389/fimmu.2025.1617589. eCollection 2025.
3
REGAL: galinpepimut-S vs. best available therapy as maintenance therapy for acute myeloid leukemia in second remission.
Future Oncol. 2025 Jan;21(1):73-81. doi: 10.1080/14796694.2024.2433935. Epub 2024 Nov 28.
4
Evolving strategies to overcome barriers in CAR-T cell therapy for acute myeloid leukemia.
Expert Rev Hematol. 2024 Nov;17(11):797-818. doi: 10.1080/17474086.2024.2420614. Epub 2024 Oct 30.
5
CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML.
Blood. 2025 Feb 13;145(7):720-731. doi: 10.1182/blood.2023023210.
6
CD97-directed CAR-T cells with enhanced persistence eradicate acute myeloid leukemia in diverse xenograft models.
Cell Rep Med. 2025 Jun 17;6(6):102148. doi: 10.1016/j.xcrm.2025.102148. Epub 2025 May 26.
7
The Problem of Molecular Target Choice for CAR-T Cells in Acute Myeloid Leukemia Therapy.
Int J Mol Sci. 2025 Jun 6;26(12):5428. doi: 10.3390/ijms26125428.
8
IL1RAP-specific T cell engager depletes acute myeloid leukemia stem cells.
J Hematol Oncol. 2024 Aug 14;17(1):67. doi: 10.1186/s13045-024-01586-x.
9
CAR-T cell therapy for treatment of acute myeloid leukemia, advances and outcomes.
Mol Ther. 2025 Jun 4;33(6):2441-2453. doi: 10.1016/j.ymthe.2025.03.052. Epub 2025 Apr 2.
10
The dual effect of interferon-γ in acute myeloid leukemia: A narrative review.
Semin Oncol. 2025 Jun;52(3):152347. doi: 10.1016/j.seminoncol.2025.152347. Epub 2025 May 5.
引用本文的文献
1
Identification and functional analysis of as a biomarker associated with immune-related genes in pediatric acute myeloid leukemia.
Transl Cancer Res. 2025 May 30;14(5):2858-2873. doi: 10.21037/tcr-24-1595. Epub 2025 May 23.
2
A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.
Nat Commun. 2025 Jun 5;16(1):5214. doi: 10.1038/s41467-025-60394-0.
3
Acute Myeloid Leukemia Skews Therapeutic WT1-specific CD8 TCR-T Cells Towards an NK-like Phenotype that Compromises Function and Persistence.
medRxiv. 2024 Dec 16:2024.12.13.24318504. doi: 10.1101/2024.12.13.24318504.
4
Membrane Antigen Targeting in Acute Myeloid Leukemia Using Antibodies or CAR-T Cells.
Cancers (Basel). 2024 Oct 28;16(21):3627. doi: 10.3390/cancers16213627.
本文引用的文献
1
CD8+ T-cell differentiation and dysfunction inform treatment response in acute myeloid leukemia.
Blood. 2024 Sep 12;144(11):1168-1182. doi: 10.1182/blood.2023021680.
2
Immunotherapy for Acute Myeloid Leukemia: Current Trends, Challenges, and Strategies.
Acta Haematol. 2024;147(2):198-218. doi: 10.1159/000533990. Epub 2023 Sep 6.
3
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects.
Signal Transduct Target Ther. 2023 Aug 18;8(1):306. doi: 10.1038/s41392-023-01521-5.
4
Mechanisms of response and resistance to combined decitabine and ipilimumab for advanced myeloid disease.
Blood. 2023 Apr 13;141(15):1817-1830. doi: 10.1182/blood.2022018246.
5
Immune dysfunction signatures predict outcomes and define checkpoint blockade-unresponsive microenvironments in acute myeloid leukemia.
J Clin Invest. 2022 Nov 1;132(21):e159579. doi: 10.1172/JCI159579.
6
Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.
Cancer Cell. 2022 Aug 8;40(8):850-864.e9. doi: 10.1016/j.ccell.2022.07.002. Epub 2022 Jul 21.
7
Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation.
Blood. 2021 Jun 10;137(23):3212-3217. doi: 10.1182/blood.2021010867.
8
Immunogenomic Landscape of Hematological Malignancies.
Cancer Cell. 2020 Sep 14;38(3):424-428. doi: 10.1016/j.ccell.2020.08.019.
9
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia.
Sci Transl Med. 2020 Jun 3;12(546). doi: 10.1126/scitranslmed.aaz0463.
10
Immune Escape of Relapsed AML Cells after Allogeneic Transplantation.
N Engl J Med. 2018 Dec 13;379(24):2330-2341. doi: 10.1056/NEJMoa1808777. Epub 2018 Oct 31.
Zotero 插件